Cipla Stock Hits 2-Year Low on US Woes, Growth Concerns

HEALTHCAREBIOTECH

Overview

Cipla's stock hit a two-year low, falling 2% while the BSE Sensex gained. The company faces ongoing issues in its US business, like gRevlimid and Lanreotide supply problems. Profitability is squeezed by lower margins. While domestic sales are strong, upcoming product launches must replace lost high-margin US revenue. Cipla will report its Q4 FY26 results on May 13, 2026.

Analyst Views and Price Targets

Analysts are generally neutral to cautious about Cipla's short-term outlook. UBS rates the stock 'Neutral' with a ₹1,400 price target, noting growth potential but also supply challenges. Nomura/Instinet has a 'Buy' rating and a ₹1,510 target, seeing upside if Cipla successfully launches new products. HSBC recommends 'Hold'.

Across 36 analysts, the average 12-month price target is ₹1,436.58, suggesting over 17% potential upside from current prices. However, this positive outlook faces pressure from significant margin contraction and US market challenges. Cipla's upcoming Q4 FY26 results, due May 13, 2026, will offer more insight into how these issues affect its recovery plan.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.